Diabetes drug tested to shield ICU patients from kidney failure
NCT ID NCT05468203
First seen Nov 01, 2025 · Last updated May 23, 2026 · Updated 27 times
Summary
This study aimed to see if dapagliflozin, a drug used for diabetes and chronic kidney disease, could prevent acute kidney injury in critically ill patients in the intensive care unit (ICU). The plan was to enroll 3000 adults at high risk for kidney damage, giving them either the drug or a placebo daily for up to 30 days. However, the study was terminated early after only 51 participants, so no conclusions can be drawn.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE KIDNEY INJURY are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Austin Health
Heidelberg, Victoria, 3084, Australia
-
Epworth Richmond
Richmond, Victoria, 3121, Australia
-
Grampians Health
Ballarat, Victoria, 3350, Australia
Conditions
Explore the condition pages connected to this study.